Operative management for recurrent and metastatic adrenocortical carcinoma
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Objective: A review of all resections for recurrent or metastatic ACC was performed to identify patients who might benefit from a surgical approach, and to identify factors that might aid in prognosis among patients with metastatic disease. Summary Background Data: Adrenocortical carcinoma (ACC) is a rare tumor, with frequent recurrences and metastases even after complete resection. Chemotherapy has limited efficacy, and surgical resection of metastatic ACC remains controversial. Methods: A retrospective review was performed of all patients who underwent surgical intervention for metastatic ACC in a single tertiary center from 1977 to 2009. All available clinicopathologic data were analyzed to determine potential factors associated with response to treatment and survival. Results: Fifty‐seven patients underwent 116 procedures for recurrent or metastatic disease. Twenty‐three resections were for liver metastases, 48 for pulmonary metastases, 22 for abdominal disease including local recurrences, and 13 were for metastases at other sites. Median and 5‐year survivals from time of first metastasectomy were 2.5 years, and 41%, respectively. The median survival of patients with DFI <12 months was 1.7 years, compared to 6.6 years for patients with DFI >12 months (P = 0.015). Median survival for right versus left‐sided primaries was 1.9 years versus 3.8 years (P = 0.03). Liver metastases were more common with right‐sided primaries (67% vs. 41%, P = 0.05). Chemotherapy had no impact on survival. Conclusions: Resection of recurrent or metastatic ACC is safe, and may result in prolongation of survival in selected patients with DFI greater than 1 year. J. Surg. Oncol. 2012; 105:709–713. © 2011 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pathologic features of prognostic significance in adrenocortical carcinoma
Weiss, L. M., Medeiros, L. J., & Vickery, A. L. (1989) · The American Journal of Surgical Pathology · doi:10.1097/00000478-198903000-00004 · Cited by 818 · cited 3×
“In our review, the number of patients receiving neoadjuvant therapy was small [5], making it difficult to draw conclusions from this group.”
BackgroundLuton, J.-P., Cerdas, S., Billaud, L., Thomas, G., Guilhaume, B., Bertagna, X., Laudat, M.-H., Louvel, A., Chapuis, Y., Blondeau, P., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199004263221705 · Cited by 717
Adrenocortical carcinoma in the United States: Treatment utilization and prognostic factors
Bilimoria, K. Y., Shen, W. T., Elaraj, D., Bentrem, D. J., Winchester, D. J., Kebebew, E., & Sturgeon, C. (2008) · Cancer · doi:10.1002/cncr.23886 · Cited by 493
Management of patients with adrenal cancer: recommendations of an international consensus conference
Schteingart, D. E., Doherty, G. M., Gauger, P. G., Giordano, T. J., Hammer, G. D., Korobkin, M., & Worden, F. P. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.01029 · Cited by 421
Schulick, R. D., & Brennan, M. F. (1999) · Annals of Surgical Oncology · doi:10.1007/s10434-999-0719-7 · Cited by 366 · cited 5×
“Consistent with observed demographics in the literature, our population was predominantly female (63%), and patients most commonly presented in the 5th–6th decade of life [2,3,6].”
BackgroundInfluentialCrucitti, F., Bellantone, R., Ferrante, A., Boscherini, M., & Crucitti, P. (1996) · Surgery · doi:10.1016/s0039-6060(96)80164-4 · Cited by 247 · cited 4×
“The median survival after complete resections ranges from 28 to 74 months in other studies [2,6,17].”
BackgroundInfluentialRadiotherapy in adrenocortical carcinoma
Polat, B., Fassnacht, M., Pfreundner, L., Guckenberger, M., Bratengeier, K., Johanssen, S., Kenn, W., Hahner, S., Allolio, B., & Flentje, M. (2009) · Cancer · doi:10.1002/cncr.24331 · Cited by 189 · cited 1×
“Radiation therapy has been used to palliate bony metastases, but ACC is generally considered radioresistant, and therefore the role of radiotherapy remains unclear [9].”
BackgroundGrubbs, E. G., Callender, G. G., Xing, Y., Perrier, N. D., Evans, D. B., Phan, A. T., & Lee, J. E. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0716-x · Cited by 158 · cited 3×
“Consistent with observed demographics in the literature, our population was predominantly female (63%), and patients most commonly presented in the 5th–6th decade of life [2,3,6].”
BackgroundLiver resection and ablation for metastatic adrenocortical carcinoma
Ripley, R. T., Kemp, C. D., Davis, J. L., Langan, R. C., Royal, R. E., Libutti, S. K., Steinberg, S. M., Wood, B. J., Kammula, U. S., Fojo, T., et al. (2011) · Annals of Surgical Oncology · doi:10.1245/s10434-011-1564-z · Cited by 62
Self-citation
Cited by
Fassnacht, M., Dekkers, O. M., Else, T., Baudin, E., Berruti, A., de Krijger, R. R., Haak, H. R., Mihai, R., Assie, G., & Terzolo, M. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0608 · Cited by 961
Fassnacht, M., Assie, G., Baudin, E., Eisenhofer, G., de la Fouchardiere, C., Haak, H. R., de Krijger, R., Porpiglia, F., Terzolo, M., & Berruti, A. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.2099 · Cited by 436
Update in Adrenocortical Carcinoma
Fassnacht, M., Kroiss, M., & Allolio, B. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3020 · Cited by 414
Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center
Ayala-Ramirez, M., Jasim, S., Feng, L., Ejaz, S., Deniz, F., Busaidy, N., Waguespack, S. G., Naing, A., Sircar, K., Wood, C. G., et al. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0519 · Cited by 293
The role of surgery in the management of recurrent adrenocortical carcinoma
Erdogan, I., Deutschbein, T., Jurowich, C., Kroiss, M., Ronchi, C., Quinkler, M., Waldmann, J., Willenberg, H. S., Beuschlein, F., Fottner, C., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2559 · Cited by 154
“Of note, all of the above-mentioned studies reported a similar pattern of recurrence (4, 7, 8, 28, 29).”
BackgroundMethodResultInfluential
Metadata
- Authors
- Datrice, N. M., Langan, R. C., Ripley, R. T., Kemp, C. D., Steinberg, S. M., Wood, B. J., Libutti, S. K., Fojo, T., Schrump, D. S., & Avital, I.
- Venue
- Journal of Surgical Oncology
- Publisher
- Wiley
- Published
- 2011-12-20
- Volume
- 105
- Issue
- 7
- Pages
- 709-713
- ISSN
- 0022-4790 (ISSN-L)
- 1096-9098
- OpenAlex
- W2065685530
- Cited by
- 101
- References
- 9
- FWCI
- 4.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Operative management for recurrent and metastatic adrenocortical carcinoma. https://app.cochat.ai/papers/10.1002/jso.23015
- The paper
- Datrice, N. M., Langan, R. C., Ripley, R. T., Kemp, C. D., Steinberg, S. M., Wood, B. J., Libutti, S. K., Fojo, T., Schrump, D. S., & Avital, I. (2012). Operative management for recurrent and metastatic adrenocortical carcinoma. Journal of Surgical Oncology. https://doi.org/10.1002/jso.23015
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.